Opinions, ideas, and research from NPLB
New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs
Insurance companies harm patients by not taking into account the true value of medicines.
One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill
NPLB released a coalition letter urging fixes to the Senate Reconciliation Drug bill.
“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs
If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.
Lawmakers Urged to Support Biopharma Innovation and Affordability
Pass reforms to lower out-of-pocket costs. Caution! Price controls could cease biopharma investment
NPLB Gets Animated: Roadmap to Patient Affordability and Innovation
Animation: Insurance Reform Needed to Cover Prescribed Medicines at Low Cost
When Simpler isn't Better
A case for generalizing cost-effectiveness math to avoid undervaluing medicines
CMS Rule to Lower Maximum Out-of-Pocket Costs by $400 Will Help Patients, More Reductions Needed
NPLB welcomed key provisions in CMS Notice of Benefit and Payment Parameters for 2022 Final Rule
NPLB Applauds Growing Momentum for Insurance Reforms that Lower Out-of-Pocket Costs for Patients
Prioritizing reforms such as drug pricing and access that help patients is essential.
Patient Out-of-Pocket Costs Continue to Climb While Insurers are Covering Fewer Drugs
Despite Reductions in Pharmaceutical Manufacturer Net Drug Prices
NPLB Applauds President’s Expansion of Affordable Healthcare
More Americans Helped, More Still to be Done
How To Kill The Conversation That Makes Innovation Possible
A short analysis
Feel free to reach out with questions, concerns, or comments.
